No Prescription |
 |
 | ||
|
Voltaren Emulgel Generic Diclofenac |
|
| ||
No Prescription » Prescription Drugs 17 » Voltaren Emulgel Generic Diclofenac Product Origin: EU (Turkey)This product is able to be sourced and supplied at excellent prices because of favourable cross border currency conversions. All products are authentic brand names and will include a product information insert in English.Voltaren is used for: Treating pain redness swelling and sensitivity to light which are symptoms related to certain eye surgeries. Diclofenac is in a group of drugs called nonsteroidal anti-inflammatory drugs (NSAIDs). Diclofenac works by reducing hormones that cause inflammation and pain in the body. Diclofenac is used to treat pain or inflammation caused by arthritis or ankylosing spondylitis. Nonsteroidal anti-inflammatory drugs (also called NSAIDs) are used to relieve some symptoms caused by arthritis (rheumatism) such as inflammation swelling stiffness and joint pain. Buy Voltaren Emulgel Generic Diclofenac and other Prescription Drugs 17 products online at Medstore. 3870
About Voltaren Emulgel Generic Diclofenac: Product Type: Prescription Drugs 17 Voltaren Emulgel ( Generic Diclofenac ) Voltaren Emulgel (Generic Diclofenac) Generic Diclofenac 10mg/gm 2 x 50g Tube Generic Diclofenac Voltaren Emulgel
View more Prescription Drugs 17 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
